Effectiveness of Ursodeoxycholic Acid Use in the Prevention of Gallstone Formation After Sleeve Gastrectomy
Cholelithiasis
About this trial
This is an interventional prevention trial for Cholelithiasis focused on measuring gallstones, cholelithiasis, sleeve gastrectomy
Eligibility Criteria
Inclusion Criteria:
- Obese patients (body mass index > 35 kg/m2) undergoing laparoscopic sleeve gastrectomy as a primary treatment for their obesity.
- No gallstone disease on initial ultrasounds
- No previous cholecystectomy
Exclusion Criteria:
- Bariatric patients with gallbladder stones on baseline ultrasound examination.
- Patients with a previous cholecystectomy
Sites / Locations
- American University of Beirut Medical CenterRecruiting
- Makassed General HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Experimental
Control
This arm will include 50 patients who, at baseline ultrasound, have no gallbladder pathology and have no previous cholecystectomy. Those patients will be taking an oral drug (Ursodeoxycholic Acid 250mg) twice daily for a period of six months and undergoing a total of three gallbladder ultrasounds (at 6 months, at 12 months, and at 18 months) to check for gallstones.
This arm will include 50 patients who, at baseline ultrasound, have no gallbladder pathology and have no previous cholecystectomy. Those patients will be taking a placebo, that is dispensed from the pharmacy and having the same color as the ursodeoxycholic acid 250mg, twice daily for a period of six months and undergoing a total of three gallbladder ultrasounds (at 6 months, at 12 months, and at 18 months) to check for gallstones.